Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A short history of neuroendocrine tumours and their peptide hormones

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic and non-iodine-related factors in the aetiology of nodular goitre

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The metabolic syndrome in HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Endocrine disorders in pregnancy: physiological and hormonal aspects of pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Genital anomalies in boys and the environment

    Research output: Contribution to journalReviewResearchpeer-review

  1. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  5. Evaluation of clinical translatability of the diet-induced obese and biopsy-confirmed gubra amylin mouse model of non-alcoholic steatohepatitis

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations
This article focusses on the antidiabetic therapeutic potential of the incretin hormone glucagon-like peptide-1 (GLP-1) in the treatment of patients with type 2 diabetes mellitus (T2DM). T2DM is characterised by insulin resistance, impaired glucose-induced insulin secretion and inappropriately regulated glucagon secretion, which in combination eventually result in hyperglycaemia and, in the longer term, microvascular and macrovascular diabetic complications. Traditional treatment modalities - even multidrug approaches - for T2DM are often unsatisfactory in making patients reach glycaemic goals as the disease progresses caused by a steady, relentless decline in pancreatic beta-cell function. Furthermore, current treatment modalities are often limited by inconvenient dosing regimens and safety and tolerability issues, the latter including hypoglycaemia, body weight gain, oedema and gastrointestinal side effects. Therefore, the actions of GLP-1, which include the potentation of meal-induced insulin secretion and trophic effects on the beta-cell, have attracted a lot of interest. GLP-1 also inhibits glucagon secretion and suppresses food intake and appetite.
Original languageEnglish
JournalBest Practice & Research: Clinical Endocrinology & Metabolism
Volume23
Issue number4
Pages (from-to)453-62
Number of pages10
ISSN1521-690X
DOIs
Publication statusPublished - 1 Aug 2009

ID: 32266457